FDA Tracker newsroom · PCAC
Day 2: the FDA panel backed Semax and Epitalon, and rejected DSIP — six of seven peptides advanced.
· Last reviewed
On July 24, the PCAC recommended Semax and Epitalon for the 503A Bulks List (tallies reported as 8–5–1 for Semax, and as 7–4–1 or 7–5–1 for Epitalon depending on the outlet; FDA has posted no minutes or transcript) but narrowly rejected Emideltide/DSIP (6–7, 1 abstention). Across both days, six of seven peptides advanced. A recommendation is not approval, not authorization, and not availability — verdict dots stay amber.
On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee closed its two-day peptide review. It recommended two more substances for the 503A Bulks List — Semax, for cerebral ischemia, migraine and trigeminal neuralgia, and Epitalon, for insomnia — and narrowly voted to recommend against Emideltide, also known as DSIP. Every tally below is AS REPORTED BY TRADE PRESS: the FDA has posted no minutes, no transcript and no vote-results summary for this meeting. Reported as Semax 8–5–1, Epitalon 7–4–1, DSIP 6–7–1. The Epitalon figure is reported as 7–4–1 by most law-firm accounts and as 7–5–1 by ArentFox Schiff, and we do not resolve the conflict — FDA's published Final Meeting Roster lists 12 members eligible to vote on that substance, and readers can weigh that themselves.
DSIP was the meeting's only rejection, and its biggest surprise: it has the longest human research record of the seven. Panelists raised a mechanistic worry — DSIP stimulates endorphin release, which several compared to the reward-pathway activity of addictive drugs — and FDA's briefing found the evidence didn't support effectiveness for the serious conditions proposed.
That makes the two-day tally six of seven recommended. As on Thursday, the favorable votes ran against the FDA's own scientific staff. And as on Thursday, a recommendation is not approval, not authorization to compound, and not availability. Placement on the Bulks List still requires the FDA to run a formal rulemaking, which realistically takes well over a year — earliest legitimate access is sometime in 2027, and only if the agency proceeds.
So the signals move as they should. For Semax and Epitalon, the regulatory pill advances to "PCAC recommended, rulemaking pending"; for DSIP it reads "PCAC declined." But every verdict dot — including DSIP's — stays amber, because none of these is available and the vote changed none of that. The regulation moved; your ability to get any of them did not.
What's next: the FDA has said a second advisory meeting will convene before the end of February 2027 to review five more peptides — LL-37, GHK-Cu, Dihexa, Melanotan II and PEG-MGF. And for the six recommended here, the milestone that actually matters is whether, and how fast, the FDA opens rulemaking.
What moved, and what did not
Regulatory status (DSIP (Emideltide)): PCAC vote in session (Jul 24) → PCAC declined · not on Bulks List path.
Plain-English verdict: unchanged (amber). A recommendation is not approval, not authorization to compound, and not availability — and a rejection does not move the dot either, because none of these was available before the vote.
Molecules in this update
Primary sources
Also reported by STAT — panel backs Epitalon & Semax, rejects Emideltide; RAPS — committee backs two more, rejects one.
Compounded medications are not FDA-approved. PCAC is an advisory committee: a favorable vote leads to FDA rulemaking, not authorization and not next-day availability. Nothing here is medical advice, and no peptide is offered for sale on this page.
Get the alert when this status actually changes · Full FDA status board · All regulatory updates